People: Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

51.84USD
22 Oct 2014
Price Change (% chg)

$-0.11 (-0.21%)
Prev Close
$51.95
Open
$52.00
Day's High
$52.30
Day's Low
$51.69
Volume
1,378,078
Avg. Vol
1,444,133
52-wk High
$57.49
52-wk Low
$46.32

Search Stocks

Summary

Name Age Since Current Position

James Cornelius

70 2013 Independent Non-Executive Chairman of the Board

Lamberto Andreotti

63 2010 Chief Executive Officer, Director

Charles Bancroft

54 2011 Chief Financial Officer, Executive Vice President

Louis Schmukler

58 2011 President - Global Manufacturing and Supply

Giovanni Caforio

49 2014 Chief Operating Officer, Director

Francis Cuss

59 2013 Executive Vice President, Chief Scientific Officer

Paul von Autenried

52 2012 Senior Vice President - Enterprise Services, Chief Information Officer

Anne Nielsen

53 2013 Senior Vice President, Chief Compliance and Ethics Officer

Joseph Caldarella

58 2010 Senior Vice President, Corporate Controller

Ann Judge

47 2013 Senior Vice President - Global Human Resources

John Elicker

54 2012 Senior Vice President - Public Affairs and Investor Relations

Brian Daniels

54 2008 Senior Vice President - Global Development & Medical Affairs, Research and Development

Frances Heller

47 2012 Senior Vice President - Business Development

Samuel Moed

51 2012 Senior Vice President - Strategic Planning and Analysis

Sandra Leung

53 2007 General Counsel, Corporate Secretary

Lewis Campbell

67 2014 Independent Director

Laurie Glimcher

62 1997 Independent Director

Michael Grobstein

71 2007 Independent Director

Alan Lacy

60 2008 Independent Director

Thomas Lynch

53 2014 Independent Director

Dinesh Paliwal

55 2013 Independent Director

Vicki Sato

65 2006 Independent Director

Gerald Storch

57 2012 Independent Director

Togo West

71 2008 Independent Director

Biographies

Name Description

James Cornelius

Mr. James M. Cornelius is Independent Non-Executive Chairman of the Board of the Board of Bristol-Myers Squibb Co He served as our Chairman and Chief Executive Officer from February 2008 to May 2010 and served as our Chief Executive Officer from September 2006 to February 2008. From November 2005 through April 2006, Mr. Cornelius served as the Chairman of the Board and Chief Executive Officer (interim) of Guidant Corporation, a U.S. cardiac and vascular medical device company. He served as Guidant's Non-Executive Chairman of the Board from 2000 until 2005.

Lamberto Andreotti

Mr. Lamberto Andreotti is Chief Executive Officer, Director of Bristol-Myers Squibb Co. Mr. Andreotti has been Chief Executive Officer since May 2010. He was our President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS. Mr. Andreotti served as Executive Vice President of BMS and President of Worldwide Pharmaceuticals from 2005-2007 and as Senior Vice President and International President of Worldwide Pharmaceuticals from 2002-2005. He is a member of Pharmaceutical Research and Manufacturers of America and The Business Council.

Charles Bancroft

Mr. Charles A. Bancroft is Chief Financial Officer, Executive Vice President of Bristol-Myers Squibb Co. He has been appointed as Executive Vice President effective October 19, 2011. He joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

Louis Schmukler

Mr. Louis S. Schmukler is President - Global Manufacturing and Supply of Bristol-Myers Squibb Co. From 2007 to 2009 he was Senior Vice President, Pharmaceutical Operating Unit, Wyeth and from 2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer.

Giovanni Caforio

Dr. Giovanni Caforio M.D., is Chief Operating Officer, Director of Bristol-Myers Squibb Co. He brings a broad range of experience to his role as chief operating officer. He joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, and assumed leadership roles for Greece, South East Europe, and in 2004, was appointed senior vice president, European Marketing and Brand Commercialization. From 2007 to 2011, Caforio helped build the company’s leadership in immuno-oncology while directing U.S. and Global oncology, and made valuable contributions to the company’s strategic focus and operational performance in roles as U.S. president and chief commercial officer from 2011 to 2014. Prior to joining Bristol-Myers Squibb, Caforio spent 12 years with Abbott Laboratories in a number of leadership positions. Caforio earned his M.D. from the University of Rome prior to joining the pharmaceutical industry.

Francis Cuss

Dr. Francis M. Cuss is Executive Vice President, Chief Scientific Officer of Bristol-Myers Squibb Co. Dr. Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. Under Dr. Cuss' leadership, Bristol-Myers Squibb has consistently been rated a research organization based on cycle time, success rates and costs, having increased discovery output while maintaining a flat operating budget. Dr. Cuss and his team integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. Dr. Cuss became a member of the company's Senior Management Team in 2010. Prior to joining Bristol-Myers Squibb, Dr. Cuss spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe. Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr. Cuss received his medical training in the U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine.

Paul von Autenried

Mr. Paul von Autenried is Senior Vice President - Enterprise Services, Chief Information Officer of Bristol-Myers Squibb Co. From 2007 to 2011 he was Vice President and Chief Information Officer, 2011 to 2012 – Senior Vice President and Chief Information Officer.

Anne Nielsen

Joseph Caldarella

Mr. Joseph C. Caldarella is Senior Vice President, Corporate Controller of Bristol-Myers Squibb Co. He was 2005 to 2010, Vice President and Corporate Controller. He was 1998 to 2005 - Vice President, Finance, Pharmaceutical Research Institute, a division of the Company.

Ann Judge

Ms. Ann Powell Judge is Senior Vice President - Global Human Resources of Bristol-Myers Squibb Co. Prior to joining Bristol-Myers Squibb, Ms. Judge was chief human resources officer at Shire Pharmaceuticals. Before Shire, Ms. Judge was corporate vice president, Human Resources, for the Pharmaceutical Division at Wyeth. During her tenure at Wyeth, Ms. Judge also held positions of responsibility for human resources in the commercial organization and in the global manufacturing unit. Previously, she spent 13 years at The Dow Chemical Company, where she worked internationally in a variety of human resources positions of increasing scope and responsibility, spending some time living and working in Germany and Switzerland. Ms. Judge has a bachelor’s degree in Psychology from the University of Iowa and a master’s degree in Industrial Relations from the University of Minnesota.

John Elicker

Mr. John E. Elicker is Senior Vice President - Public Affairs and Investor Relations of Bristol-Myers Squibb Co. He served as 2000 to 2002 – Senior Director, Investor Relations, 2002 to 2010 –Vice President, Investor Relations, 2010 to 2012 – Senior Vice President, Investor Relations.

Brian Daniels

Dr. Brian Daniels M.D., is Senior Vice President - Global Development & Medical Affairs, Research and Development of Bristol-Myers Squibb Co. In this position, he helps drive the company’s focus on science and medicine as a central strategy of the company's next-generation BioPharma vision. Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept. In 2002, Brian was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE. He also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations. He was appointed senior vice president, Global Clinical Development in 2004, and to his current position in March 2008. Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research, where he held the role of senior director, Pulmonary and Immunology. He has also worked in clinical research at Genentech. He holds bachelor’s and master’s degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine. He received training in internal medicine at New York Hospital and in rheumatology at the University of California in San Francisco.

Frances Heller

Ms. Frances K. Heller, J.D. is Senior Vice President - Business Development of Bristol-Myers Squibb Co. Prior to joining Bristol-Myers Squibb, Ms. Heller was executive vice president, Business Development at Exelixis. Prior to that, Ms. Heller was head of Strategic Alliances at Novartis Pharmaceuticals where she was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Previously, she was Corporate and Intellectual Property counsel for Celera Genomics. Ms. Heller serves on the board of directors of several biotech companies and universities, is a Trustee at the Dana Farber Cancer Institute and teaches a business class at Stanford University on the biotech and pharmaceutical industry. Ms. Heller is a member of the California State Bar, is licensed by the U.S. Patent and Trademark Office, and has a B.S. in biology from Tulane University, an M.A. in biology from American University, and a J.D. from Golden Gate University School of Law.

Samuel Moed

Mr. Samuel J. Moed is Senior Vice President - Strategic Planning and Analysis of Bristol-Myers Squibb Co. He served as 2005 to 2010 – Senior Vice President, Worldwide Strategy and Operations, 2010 to 2012 – Senior Vice President, Strategy.

Sandra Leung

Ms. Sandra Leung is General Counsel, Corporate Secretary of Bristol-Myers Squibb Co. She joined Bristol-Myers Squibb in 1992 as a staff attorney in the litigation department. In 1996 she became assistant counsel and one year later, was named associate counsel. In 1999, Sandy was appointed to the position of counsel and corporate secretary, and in 2002 became corporate vice president. Four years later, Sandy was named acting general counsel in addition to her other duties, and in 2007, she was named to her current position as senior vice president and general counsel. Before joining the company, Sandy spent eight years as a prosecutor in the Manhattan District Attorney’s office and was one of New York City’s first Asian-American female prosecutors. During her time there, she was part of the original special victims unit. She earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.

Lewis Campbell

Mr. Lewis B. Campbell is Independent Director of Bristol-Myers Squibb Co. He has served as the Executive Chairman and Interim Chief Executive Officer of Navistar International Corporation, a leading manufacturer of commercial trucks, buses, RVs, defense vehicles and engines, from August 2012 to April 2013. Prior to that, Mr. Campbell served as Non-Executive Chairman of Textron Inc. from December 2009 to August 2010 and served as Chairman and Chief Executive Officer of Textron from February 1999 through November 2009 when he retired as Chief Executive Officer. Mr. Campbell is a member of The Business Council. Mr. Campbell served as our Lead Independent Director from February 2008 through March 2014.

Laurie Glimcher

Dr. Laurie H. Glimcher M.D., is Independent Director of Bristol-Myers Squibb Co. She has served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs since January 2012. She had been the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School from 1990 to December 2011. She is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and a member of the Institutes of Medicine of the National Academy of Sciences. She is also a member and past President of the American Association of Immunologists. She was elected to the American Society of Clinical Investigation, the American Association of Physicians and the American Association for the Advancement of Science.

Michael Grobstein

Mr. Michael Grobstein is Independent Director of Bristol-Myers Squibb Co. He is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. Mr. Grobstein worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975. He served as a Vice Chairman-International Operations from 1993 to 1998, as Vice Chairman-Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman-Accounting and Auditing Services from 1984 to 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc.

Alan Lacy

Mr. Alan J. Lacy is Independent Director of Bristol-Myers Squibb Co. He has been a Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, since 2007. From 1994 to 2006, he was employed by Sears, Roebuck and Co., a large retail company, and following its acquisition, Sears Holdings Corporation, a large broadline retailer. Mr. Lacy held executive level positions of increasing responsibility in finance and operations, including his service as Chief Executive Officer and Chairman of the Board from 2000 to 2005. He also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. He is Trustee and former Chairman of the National Parks Conservation Association.

Thomas Lynch

Dr. Thomas J. Lynch, Jr., M.D., is Independent Director of the company since January 1, 2014. has served as the Director of Yale Cancer Center and has been the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine since 2009. He has also served as the Physician-in-Chief of Smilow Cancer Hospital, Yale-New Haven since 2009. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He also serves as a Director on the boards of the Kenneth B. Schwartz Center for Compassionate Healthcare and the Pearlpoint Foundation and is a member of the Scientific Advisory Board of Arvinas, Inc.

Dinesh Paliwal

Mr. Dinesh C. Paliwal Independent Director of Bristol-Myers Squibb Company. He has served as Executive Chairman, President and Chief Executive Officer of Harman International Industries, Inc., a company that designs, manufactures and markets a wide range of audio and information solutions for the automotive, consumer and professional market, since July 2008. Mr. Paliwal has served as President and Chief Executive Officer of Harman since July 2007. Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007. Mr. Paliwal also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005. Mr. Paliwal is a member of the CEO Business Roundtable.

Vicki Sato

Dr. Vicki L. Sato Ph.D., is Independent Director of Bristol-Myers Squibb Co. She has been a professor of management practice at the Harvard Business School and professor of the practice of molecular and cell biology at Harvard University since July 2005. In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal, and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chair of the Scientific Advisory Board at Vertex before being named President in 2000.

Gerald Storch

Mr. Gerald L. Storch is Independent Director of Bristol-Myers Squibb Co. He has served as Chairman and Chief Executive Officer of Storch Advisors since November 2013. He served as Chairman of Toys"R"Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys"R"Us from February 2006 to May 2013. Prior to joining Toys"R"Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. He is a director of Fanatics, Inc.

Togo West

Honourable Togo Dennis West, Jr., is Independent Director of Bristol-Myers Squibb Co. He has been Chairman of TLI Leadership Group, a strategic consulting firm since 2006 and Chairman of Noblis, Inc., a nonprofit science and technology company since 2001. From 2004 to 2006, Secretary West was the Chief Executive Officer of the Joint Center for Political and Economic Studies, a nonprofit research and public policy institution. He served as Of Counsel to the Washington, D.C. based law firm of Covington & Burling from 2000 to 2004. Secretary West served as U.S. Secretary of Veterans Affairs from 1998 to 2000 and as U.S. Secretary of the Army from 1993 to 1997.
Search Stocks